67 Participants Needed

IO-202 + Azacitidine/Venetoclax for AML and CMML

Recruiting in Cleveland (>99 mi)
+25 other locations
PW
LW
YT
KG
YT
Overseen ByYasuhiro Tabata, MD, PhD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differentiation and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D)

Who Is on the Research Team?

HX

Hong Xiang, PhD

Principal Investigator

Immune-Onc Therapeutics

Are You a Good Fit for This Trial?

This trial is for adults (18+) with certain types of blood cancer: relapsed or refractory Acute Myeloid Leukemia (AML) with specific differentiation, or Chronic Myelomonocytic Leukemia (CMML). Participants must have failed previous treatments and be in good enough health to give consent and undergo regular bone marrow/blood tests. Pregnant women, those with other severe illnesses, recent transplants, or known allergies to similar drugs cannot join.

Inclusion Criteria

I have CMML and have never been treated with hypomethylating agents.
I have AML that didn't respond to treatment and fits specific types.
I have CMML that didn't respond to treatment or has come back.
See 10 more

Exclusion Criteria

I currently have an active infection.
Patients with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol
Patients who are pregnant or breastfeeding
See 20 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

Participants receive IO-202 monotherapy or IO-202 plus Azacitidine in ascending doses to assess safety and tolerability

28-day cycles
Multiple visits per cycle

Dose Expansion

Participants receive IO-202 plus Azacitidine ± Venetoclax to further evaluate safety and clinical activity

28-day cycles
Multiple visits per cycle

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Azacitidine
  • IO-202
  • Venetoclax
Trial Overview The study is testing IO-202 alone and combined with Azacitidine ± Venetoclax in patients with AML and CMML. It aims to find the safest high dose (MTD/MAD) for future studies by gradually increasing amounts in different groups of participants until they reach a level that's effective but tolerable.
How Is the Trial Designed?
5Treatment groups
Experimental Treatment
Group I: Dose Expansion of IO-202 plus Azacitidine CMMLExperimental Treatment1 Intervention
Group II: Dose Expansion of IO-202 plus Azacitidine AMLExperimental Treatment1 Intervention
Group III: Dose Expansion of IO-202 plus Azacitidine + Venetoclax (Ven)Experimental Treatment1 Intervention
Group IV: Dose Escalation of IO-202 Plus AzacitidineExperimental Treatment1 Intervention
Group V: Dose Escalation of IO-202Experimental Treatment1 Intervention

Azacitidine is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺
Approved in European Union as Vidaza for:
🇺🇸
Approved in United States as Vidaza for:
🇨🇦
Approved in Canada as Vidaza for:
🇯🇵
Approved in Japan as Vidaza for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Immune-Onc Therapeutics Inc

Lead Sponsor

Trials
3
Recruited
180+

Immune-Onc Therapeutics

Lead Sponsor

Trials
5
Recruited
740+

California Institute for Regenerative Medicine (CIRM)

Collaborator

Trials
70
Recruited
3,300+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security